IL217537A0 - Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide - Google Patents
Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamideInfo
- Publication number
- IL217537A0 IL217537A0 IL217537A IL21753712A IL217537A0 IL 217537 A0 IL217537 A0 IL 217537A0 IL 217537 A IL217537 A IL 217537A IL 21753712 A IL21753712 A IL 21753712A IL 217537 A0 IL217537 A0 IL 217537A0
- Authority
- IL
- Israel
- Prior art keywords
- oxy
- ylpropyl
- dicarboxamide
- methyloxy
- quinolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22650909P | 2009-07-17 | 2009-07-17 | |
PCT/US2010/042353 WO2011009095A1 (en) | 2009-07-17 | 2010-07-16 | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
IL217537A0 true IL217537A0 (en) | 2012-02-29 |
Family
ID=42712017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL217537A IL217537A0 (en) | 2009-07-17 | 2012-01-15 | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
Country Status (15)
Country | Link |
---|---|
US (1) | US8673912B2 (ja) |
EP (1) | EP2454238A1 (ja) |
JP (1) | JP2012533570A (ja) |
KR (1) | KR20120051702A (ja) |
CN (1) | CN102510855B (ja) |
AU (1) | AU2010274012A1 (ja) |
BR (1) | BR112012001118A2 (ja) |
CA (1) | CA2768370A1 (ja) |
EA (1) | EA201200144A1 (ja) |
IL (1) | IL217537A0 (ja) |
MX (1) | MX2012000809A (ja) |
NZ (1) | NZ597695A (ja) |
TW (1) | TW201118072A (ja) |
WO (1) | WO2011009095A1 (ja) |
ZA (1) | ZA201200389B (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4638436B2 (ja) | 2003-09-26 | 2011-02-23 | エグゼリクシス, インコーポレイテッド | c−Metモジュレーターおよびその使用 |
TW201920110A (zh) | 2009-01-16 | 2019-06-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
CN102933551A (zh) * | 2010-03-12 | 2013-02-13 | 埃克塞里艾克西斯公司 | N-[3-氟-4-({6-(甲氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺的水合结晶形式 |
KR101862324B1 (ko) | 2010-07-16 | 2018-05-29 | 엑셀리시스, 인코포레이티드 | C-met 조절제 약제학적 조성물 |
EP2621481B2 (en) | 2010-09-27 | 2022-10-19 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
TW201309650A (zh) | 2011-02-10 | 2013-03-01 | Exelixis Inc | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
EP2704717A1 (en) | 2011-05-02 | 2014-03-12 | Exelixis, Inc. | Method of treating cancer and bone cancer pain |
ES2639093T3 (es) | 2011-09-22 | 2017-10-25 | Exelixis, Inc. | Procedimiento para el tratamiento de la osteoporosis |
WO2013059788A1 (en) | 2011-10-20 | 2013-04-25 | Exelixis, Inc. | Process for preparing quinoline derivatives |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
EA033786B1 (ru) | 2013-03-15 | 2019-11-26 | Exelixis Inc | Метаболиты n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида |
CA2908815A1 (en) * | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Drug combinations to treat cancer |
US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
US10501418B2 (en) | 2014-02-14 | 2019-12-10 | Exelixis, Inc. | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
MA39735A (fr) | 2014-03-17 | 2017-01-25 | Exelixis Inc | Dosage de préparations de cabozantinib |
ES2929888T3 (es) | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
KR102634247B1 (ko) | 2014-08-05 | 2024-02-05 | 엑셀리시스, 인코포레이티드 | 다발성 골수종을 치료하기 위한 약물 병용물 |
MA44672A (fr) | 2016-04-15 | 2019-02-20 | Exelixis Inc | Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
MX2018013764A (es) | 2016-05-16 | 2019-08-05 | Gb001 Inc | Cristal de derivado de quinolina. |
KR20210105931A (ko) * | 2018-12-20 | 2021-08-27 | 머크 샤프 앤드 돔 코포레이션 | Nrtti 화합물의 신규 결정질 형태 |
CN110357814A (zh) * | 2019-07-12 | 2019-10-22 | 上海翔锦生物科技有限公司 | 对甲苯磺酸盐新晶型及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4342935B2 (ja) | 2001-06-22 | 2009-10-14 | 協和発酵キリン株式会社 | 肝細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
JP4638436B2 (ja) | 2003-09-26 | 2011-02-23 | エグゼリクシス, インコーポレイテッド | c−Metモジュレーターおよびその使用 |
KR20110084455A (ko) | 2008-11-13 | 2011-07-22 | 엑셀리시스, 인코포레이티드 | 퀴놀린 유도체를 제조하는 방법 |
-
2010
- 2010-07-16 AU AU2010274012A patent/AU2010274012A1/en not_active Abandoned
- 2010-07-16 EA EA201200144A patent/EA201200144A1/ru unknown
- 2010-07-16 TW TW099123569A patent/TW201118072A/zh unknown
- 2010-07-16 EP EP10737177A patent/EP2454238A1/en not_active Withdrawn
- 2010-07-16 CA CA2768370A patent/CA2768370A1/en not_active Abandoned
- 2010-07-16 KR KR1020127004144A patent/KR20120051702A/ko not_active Application Discontinuation
- 2010-07-16 WO PCT/US2010/042353 patent/WO2011009095A1/en active Application Filing
- 2010-07-16 JP JP2012520827A patent/JP2012533570A/ja active Pending
- 2010-07-16 BR BR112012001118A patent/BR112012001118A2/pt not_active IP Right Cessation
- 2010-07-16 US US13/384,451 patent/US8673912B2/en active Active
- 2010-07-16 CN CN201080042037.0A patent/CN102510855B/zh not_active Expired - Fee Related
- 2010-07-16 MX MX2012000809A patent/MX2012000809A/es not_active Application Discontinuation
- 2010-07-16 NZ NZ597695A patent/NZ597695A/en not_active IP Right Cessation
-
2012
- 2012-01-15 IL IL217537A patent/IL217537A0/en unknown
- 2012-01-18 ZA ZA2012/00389A patent/ZA201200389B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2012533570A (ja) | 2012-12-27 |
KR20120051702A (ko) | 2012-05-22 |
WO2011009095A1 (en) | 2011-01-20 |
CN102510855A (zh) | 2012-06-20 |
EA201200144A1 (ru) | 2012-08-30 |
US20120270872A1 (en) | 2012-10-25 |
ZA201200389B (en) | 2012-09-26 |
US8673912B2 (en) | 2014-03-18 |
BR112012001118A2 (pt) | 2016-02-23 |
CN102510855B (zh) | 2015-11-25 |
CA2768370A1 (en) | 2011-01-20 |
NZ597695A (en) | 2014-05-30 |
MX2012000809A (es) | 2012-03-14 |
WO2011009095A8 (en) | 2011-03-24 |
EP2454238A1 (en) | 2012-05-23 |
TW201118072A (en) | 2011-06-01 |
AU2010274012A1 (en) | 2012-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL217537A0 (en) | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide | |
ZA201206679B (en) | Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | |
IL234097A0 (en) | Malate salt of n-(4-{[-7,6-bis(methyloxy)quinolin-4-yl]oxy}phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for treatment in cancer | |
ZA201605424B (en) | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use | |
IL231495B (en) | N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide compounds or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of osteoporosis | |
EP2753389A4 (en) | CANNULAR TIPS, TISSUE RETAINING RINGS AND METHOD FOR THE DELIVERY AND USE THEREOF | |
IL217768A (en) | Coinimod for the treatment of Crohn's disease | |
HK1196131A1 (zh) | 用於治療或預防呼吸道合胞病毒疾病的化合物 | |
PL3064206T3 (pl) | Leczenie choroby Huntingtona z zastosowaniem lakwinimodu | |
EP2684877A4 (en) | PHARMACEUTICALLY ACCEPTABLE SALT OF (E) -N- [4 - [[3-CHLORO-4- (2-PYRIDYLMETHOXY) PHENYL] AMINO] -3-CYANO-7-ETHOXY-6-QUINOLYL] -3 - [(2R) -1-METHYLPYRROLIDIN-2-YL] PROP-2-ENAMIDE, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | |
EP2387561A4 (en) | IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS | |
IL230487B (en) | 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them | |
EP2586768A4 (en) | HYDROXYACID COMPOUND OF SUBSTITUTED PHENYL ESTER, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | |
IL241577B (en) | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide | |
HK1186671A1 (en) | Formulations for the treatment of disorders of the upper respiratory tract | |
IL230484A (en) | "6- (n- (7-Chloro-1-Hydroxy-1, 3-Dihydrobenzo [c] [1,2] Oxaborol-5-Yl) - Methylbenzoforan-3 - Carbamamide and a Pharmaceutical Preparation | |
IL260078B (en) | Therapy used to treat Gaucher disease | |
EP2611788A4 (en) | NICOTINE COMPOUNDS AND THEIR ANALOGUES, SYNTHESIS METHODS FOR MAKING COMPOUNDS AND METHODS OF USE | |
ZA201207696B (en) | Compound for treatment of respiratory condition or disease | |
IL213770A (en) | Use of Fibert to prepare a drug to treat sleep apnea | |
PL2521727T3 (pl) | Nowe benzoesowe pochodne pirolopirydyny i ich zastosowanie w leczeniu choroby parkinsona | |
SI2387563T1 (sl) | Malatna sol N-(4-((6,7-bis(metiloksi)kinolin-4-il)oksi)fenil-N'-(4-lurofenil)-ciklo- propan-1,1-dikarboksamida in njene kristalinične oblike za zdravljenje raka | |
GB201018362D0 (en) | Treatment of dupuytren's disease | |
AU2010901601A0 (en) | Compound for the treatment of respiratory condition or disease | |
TH0901004168A (th) | เกลือของ n-[6-(ซิส-2,6-ไดเมทธิลมอร์โฟลิน-4-อิล)ไพริดีน-3-อิล]-2-เมทธิล-4'-(ไตรฟลูออโรเมทธอกซี)[1,1'-ไบฟีนิล]-3-คาร์บอกซาไมด์ |